Oncoinvent AS is looking for an Engineer to strengthen the Quality Control team at the manufacturing facility in Oslo. The position is an exciting opportunity to work in an innovative and dynamic company and participate in the development of novel pharmaceuticals.
The successful candidate will, together with the Quality Control team be responsible for quality control of raw materials, intermediates and drug product (Radspherin®) and for environmental monitoring of the cleanrooms.
Qualifications and experience:
The holder of the Senior Research Scientist Drug Development position should have the following documented qualifications and experience:
The holder of this position should have the following documented qualifications and experience:
The holder of this position will be based at Oncoinvent AS, Gullhaugveien 7, 0484 Oslo. The position will report to the Head of Quality.
Oncoinvent is a privately held Norwegian company based in Nydalen, Oslo. The company is committed to developing novel, innovative products to provide better treatment options for cancer patients. The Oncoinvent team consists of 27 employees and the company is growing. In December 2017 Oncoinvent finished building a state-of-the-art manufacturing facility to produce drug product intended for use pre-clinical and early phase clinical trials.
Application deadline: 31. Oct. 2020
Gro Elisabeth Hjellum, Head of Quality Control, CMC Coordinator
Mobile: +47 97 98 30 92
+47 464 40 045
Jan A. Alfheim is a business executive with over thirty years’ experience bringing product ideas and technology to the chemical and pharmaceutical markets, from product concept inception through discovery and development phases to final marketing campaign and launch.
With experience in research, project management, business development & partnering, company start-ups, and product launches, Alfheim comes from Nordic Nanovector ASA where he was Chief Executive Officer from 2011 until 2014 and Chief Operating Officer from 2014 to 2016. Prior to working at Nordic Nanovector, he has held various senior roles including Chief Business Officer at Clavis Pharma, President of StemPath Inc, Director of Business Development at Neurochem Inc and Project Director at Nycomed Imaging. Mr. Alfheim holds a MSc from Concordia University and a MBA from McGill University.